tion of digoxin bioavailability in single-dose studies. N Engi J Med 289, 651-654 (1973 The advantages of measuring urinary estriol-16a-glucuronide (E3-16a-G) instead of total estriol for the purpose of monitoring fetal well-being have been recognized (1-4) . Various direct radioimmunoassay (RT.A)procedures have been developed for monitoring E3-16a-G in pregnancy urine (4-9); but some of these methods lack specificity, involve time-consuming incubation and phase-separation steps, and depend upon the availability of a suitable radiolabeled ligand.
In this relatively simple, rapid assay of estriol-16a-glucuronide in pregnancy urine, the urine sample is diluted 20-fold with phosphate buffer (pH 5.2) containing 360 mL of acetonitnle and 2 g of cetyltrimethylammonium bromide per liter, then directly injected into the chromatograph. A sample can be assayed within 14 mm. Day-to-day CV5 ranged from 2.3% at 45 mg/L to 2.9% at 4.8 mg/L. The limit of sensitivity is 0.4 mg/L. Results by the present method (y) correlated and compared very well with those by a method involving fractionation of estrogen conjugates and gas chromatography (x) for 24 samples of pregnancy urine (y = 1.09x + 0.303; r = 0.947). This assay is inexpensive and suitable for complete automation.
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The advantages of measuring urinary estriol-16a-glucuronide (E3-16a-G) instead of total estriol for the purpose of monitoring fetal well-being have been recognized (1) (2) (3) (4) . Various direct radioimmunoassay (RT.A)procedures have been developed for monitoring E3-16a-G in pregnancy urine (4) (5) (6) (7) (8) (9) ; but some of these methods lack specificity, involve time-consuming incubation and phase-separation steps, and depend upon the availability of a suitable radiolabeled ligand.
Alternatively, chemiluminescence assays have been proposed (10, 11) , which only partly satisfy the requirements of rapidity and simplicity.
The feasibility of"high-performance" liquid chromatography (HPLC) for direct measurement of E3-16a-G in pregnancy urine has been investigated. However, one proposed method involves a relatively nonselective detector and an unsuitable mobile phase for the elution of the estriol metabolite (12), and another involves derivatization of the estriol conjugate before quantification by fluorimetry We describe here a direct HPLC procedure with fluorimetric detection, which exploits ion-pair, reversed-phase chromatography and the native fluorescence of E3-16a-G. This assay is extremely simple, rapid, and completely suitable for automation.
Materials and Methods
'Dipartimento di Chimica, Universit#{224} "La Sapienza"di Roma, Piazza Aldo More 5, 00185 Roma, Italy. 
HPLC apparatus.
We used a Series 1 liquid chromatograph equipped with a Model 650-lOS fluorescence detector having a 20-L flow cell and a Rheodyne Model 7125 injectorwith a 20-FL loop (all from Perkin-Elmer
Corp., Norwalk, CT 06856). We used a 4.6 mm x 25 cm column filled with 5-gm (av. particle size) C18reversed-phase packing and a guard column containing "Pelliguard," both from Supelco Inc., Bellefonte, PA 16823. As mobile phase, we used acetonitrile/phosphate buffer (20 mmol/L; pH 5.2), 36/64 by vol, in which we dissolved 2.0 g of cetyltrimethylammonium bromide per liter of mobile phase. The flow rate was 1.5 mL/min. We monitored E3-16a-G fluorimetrically, with excitation and emission wavelengths of the detector set at 280 and 308 rim, respectively, and 12-nm slit widths.
Estriol-3-glucuronide

Reagents.
"Chromatography-grade"
acetonitrile was from Carlo Erba, Milano, Italy. Water was distilled in a glass system in the presence of permanganate. Cetyltrimethylammonium bromide was from Merck, Darmstadt, F.R.G. Working phosphate buffer,pH 5.2, was prepared by dissolving 2.76 g of NaH2PO4 H20 in 1 L of freshly distilled water and adjusting the pH to 5.2 with NaOH, 0.1 mol/L. Estriol-3-sulfate-16a-glucuronide was synthesized from E3-l6a-G according to Levitz et al. (17) . E3-16a-G and the other estrogen conjugates were from Sigma Chemical Co., St. Louis, MO 63178. Stock E3-16a-G standard was dissolved in methanol at 1 g/L and later diluted with methanol to give 10 ,ug/L working standard. 
Results
The excitation and emission spectra of the native molar fluorescence of the E3-16a-G were recorded and compared with those of the estriol. We observed that introduction of a glucuronide group in position 16 does not substantially modify the native fluorescence of the estriol molecule. nide, analogously to estrone and its derivatives, is not fluorescent under the detection conditions selected.
Interferences.
Under our experimental
We evaluated the extent of background interference eluting at the same time as E3-16a-G by analyzing urine samples from 18 nonpregnant women. The background was <0.1 mg/L of urine, and this does not interfere.
As a final check on the specificity of the assay, we ascertained the absence of interferences from any other minor-abundance estrogen conjugates by analyzing 25 samples of late-pregnancy urine. For any sample, we collected from the column outlet an appropriate volume fraction of the mobile phase supposed to contain all the chromatographic band of the E3-16a-G. The solution was evaporated, the residue was submitted to enzymic hydrolysis, and the estriol so liberated was analyzed according to a procedure  reported elsewhere (19). On expressing data for E3-16a-G 
Sensitivity.
The limit of sensitivity (signallnoise ratio = 3) was 0.4 mg/L of urine. For this concentration the CV was 5.2%.
Precision.
Seven selected urine samples were each assayed six times during a month. The day-to-day CVs ranged from 2.3% at 45 mg/L to 2.9% at 4.8 mg/L. We assessed the day-to-day variation of E3-16a-G urinary excretion by analyzing 24 pairs of 24-h urine samples collected on two consecutive days from 24 apparently normal, ambulant women in their third trimester pregnancy. The CV was 8.3%. This finding gives additional evidence of the low day-to-day fluctuations in E3-16a-G excretion (4). Interestingly, the day-to-day variations of urinary E3-16a-G we measured are significantly lower than those relative to both unconjugated and total estriol in pregnancy plasma (23).
Discussion
Outstanding features of this assay are its rapidity and simplicity.
A single assay can be completed within 14 mm of its receipt, and sample manipulation is reduced to a minimum, thus eliminating almost at all possibilities of errors in a clinical laboratory. In addition, this procedure can be easily adapted to automatic sampling and data-reduction devices now commercially available, thus making it even simpler.
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